Immunic Inc [IMUX] stock prices are down -0.92% to $0.84 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The IMUX shares have lost -6.71% over the last week, with a monthly amount glided 2.74%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Immunic Inc [NASDAQ: IMUX] stock has seen the most recent analyst activity on September 29, 2025, when Chardan Capital Markets initiated its Buy rating and assigned the stock a price target of $13. On November 25, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $10 on the stock. B. Riley Securities initiated its recommendation with a Buy and recommended $6 as its price target on August 27, 2024. SVB Leerink downgraded its rating to Mkt Perform for this stock on October 21, 2022, but kept the price target unchanged to $5.
The stock price of Immunic Inc [IMUX] has been fluctuating between $0.56 and $1.73 over the past year. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. Immunic Inc [NASDAQ: IMUX] shares were valued at $0.84 at the most recent close of the market. An investor can expect a potential return of 495.24% based on the average IMUX price forecast.
Analyzing the IMUX fundamentals
Gross Profit Margin for this corporation currently stands at -0.62% with Operating Profit Margin at -923.38%, Pretax Profit Margin comes in at -893.3%, and Net Profit Margin reading is -893.3%. To continue investigating profitability, this company’s Return on Assets is posted at -1.66, Equity is -4.61 and Total Capital is -3.09. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Immunic Inc [NASDAQ:IMUX]’s Current Ratio is 2.19. As well, the Quick Ratio is 2.19, while the Cash Ratio is 2.03.
Transactions by insiders
Recent insider trading involved Nash Duane, Executive Chairman, that happened on Jun 13 ’25 when 20000.0 shares were purchased. President and COO, Tardio Jason completed a deal on Jun 05 ’25 to buy 12512.0 shares. Meanwhile, CEO and Director Vitt Daniel bought 15000.0 shares on Jun 04 ’25.
